Drugs.com Clinical Trial ResultsOriginal article
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Phase 3ZanzalintinibNeutral
AI Analysis
Summary
Exelixis announced final analysis results from the Phase 3 STELLAR-303 trial of Zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer patients, reporting on the dual primary endpoint of overall survival in the subset without active liver metastases.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Final analysis of dual primary endpoint (overall survival) in subset of patients without active liver metastases
Importance:7/10
Sentiment:
0.00
Phase 3Colorectal cancerCombination therapyImmune checkpoint inhibitor
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 22, 2026 2:06 AM